78 results
Page 2 of 4
8-K
EX-99.1
kjluq11pjr1zzj yqf5
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
EX-99.1
cnv50me
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm
8-K
EX-99.1
ag98wh7 hg5oi6
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
ee396a4p5x s0h8f76tl
30 Sep 20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
8:05am
8-K
EX-1.1
ke0p lbzhwkptm
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
424B5
var 3kkqym9
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
yixbzqkpf3e00csm p43
25 Aug 20
Other Events
7:00am
8-K
EX-99.1
mb0in5 tx4i
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
EX-99.1
t4r9bvk0i9opa4hohdg
30 Mar 20
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
8:05am
8-K
EX-99.1
nshdrwq3yfqgef4
13 Mar 20
Regulation FD Disclosure
9:06am
8-K
EX-99.1
acx6i3c ci
11 Mar 20
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
8:05am